文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

接受高流量氧疗的急性呼吸窘迫综合征患者的亚表型

Subphenotypes in patients with acute respiratory distress syndrome treated with high-flow oxygen.
PubMed 文献 · Crit Care · 2023-11-01
一句话结论在接受高流量鼻氧治疗的ARDS患者中,基于IL-8和sST2的HAIS评分(≥7.45)可识别高炎症亚表型,该亚表型60天死亡率更高(47% vs 8.3%)。

该研究是对一项前瞻性多中心观察性研究的二次分析,纳入41例接受高流量鼻氧支持的ARDS患者,检测血浆炎症标志物(IL-6、IL-8、IL-33、sST2)、肺上皮损伤标志物(RAGE、SP-D)和内皮损伤标志物(Ang-2)及碳酸氢盐,采用K-means聚类分析识别亚表型。结果识别出两个亚表型:高炎症亚表型(n=17)和低炎症亚表型(n=24)。尽管基线特征相似,高炎症亚表型60天死亡率更高(47% vs 8.3%,p=0.014),ICU住院时间更长(22.0天[18.0-30.0] vs 39.5天[25.5-60.0],p=0.034)。基于IL-8和sST2的HAIS评分能准确区分亚表型(AUROC 0.96 [95%CI: 0.90-1.00]),HAIS评分≥7.45是高炎症亚表型的预测因子。作者认为HAIS评分可能用于未来临床试验的富集策略。

要点

  • 在接受HFNO治疗的ARDS患者中识别出高炎症和低炎症两个生物学亚表型,高炎症亚表型60天死亡率更高(47% vs 8.3%,p=0.014)。
  • 高炎症亚表型ICU住院时间更长(22.0天[18.0-30.0] vs 39.5天[25.5-60.0],p=0.034)。
  • 基于IL-8和sST2的HAIS评分可准确区分亚表型,AUROC为0.96(95%CI: 0.90-1.00)。
  • HAIS评分≥7.45是高炎症亚表型的预测因子。
  • 作者认为HAIS评分可能用于未来临床试验的富集策略。

适用人群与场景

  • 接受高流量鼻氧(HFNO)支持的ARDS患者,来自一项前瞻性多中心观察性研究,共41例。

诊断标准与关键阈值

  • HAIS评分基于IL-8和sST2,HAIS评分≥7.45预测高炎症亚表型。

研究设计与关键结果

  • 研究类型:前瞻性多中心观察性研究的二次分析;样本量41例HFNO治疗的ARDS患者;识别出两个亚表型:高炎症亚表型(n=17)和低炎症亚表型(n=24)。
  • 高炎症亚表型生物标志物水平高于低炎症亚表型;尽管基线特征相似,高炎症亚表型60天死亡率更高(47% vs 8.3%,p=0.014),ICU住院时间更长(22.0天[18.0-30.0] vs 39.5天[25.5-60.0],p=0.034)。
  • HAIS评分基于IL-8和sST2,区分亚表型的AUROC为0.96(95%CI: 0.90-1.00);HAIS评分≥7.45为高炎症亚表型的预测因子。

证据类型、等级与局限

  • 证据类型:前瞻性多中心观察性研究的二次分析;局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为HAIS评分可能识别高炎症亚表型患者,并可能用于未来临床试验的富集策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Acute respiratory distress syndrome (ARDS) subphenotypes differ in outcomes and treatment responses. Subphenotypes in high-flow nasal oxygen (HFNO)-treated ARDS patients have not been investigated.

OBJECTIVES: To identify biological subphenotypes in HFNO-treated ARDS patients.

METHODS: Secondary analysis of a prospective multicenter observational study including ARDS patients supported with HFNO. Plasma inflammation markers (interleukin [IL]-6, IL-8, and IL-33 and soluble suppression of tumorigenicity-2 [sST2]) and lung epithelial (receptor for advanced glycation end products [RAGE] and surfactant protein D [SP-D]) and endothelial (angiopoietin-2 [Ang-2]) injury were measured. These biomarkers and bicarbonate were used in K-means cluster analysis to identify subphenotypes. Logistic regression was performed on biomarker combinations to predict clustering. We chose the model with the best AUROC and the lowest number of variables. This model was used to describe the HAIS (High-flow ARDS Inflammatory Subphenotype) score.

RESULTS: Among 41 HFNO patients, two subphenotypes were identified. Hyperinflammatory subphenotype (n = 17) showed higher biomarker levels than hypoinflammatory (n = 24). Despite similar baseline characteristics, the hyperinflammatory subphenotype had higher 60-day mortality (47 vs 8.3% p = 0.014) and longer ICU length of stay (22.0 days [18.0-30.0] vs 39.5 [25.5-60.0], p = 0.034). The HAIS score, based on IL-8 and sST2, accurately distinguished subphenotypes (AUROC 0.96 [95%CI: 0.90-1.00]). A HAIS score ≥ 7.45 was predictor of hyperinflammatory subphenotype.

CONCLUSION: ARDS patients treated with HFNO exhibit two biological subphenotypes that have similar clinical characteristics, but hyperinflammatory patients have worse outcomes. The HAIS score may identify patients with hyperinflammatory subphenotype and might be used for enrichment strategies in future clinical trials.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Blot PL, Chousterman BG, Santafè M, et al. Subphenotypes in patients with acute respiratory distress syndrome treated with high-flow oxygen. Crit Care. 2023. PMID: 37915062. doi:10.1186/s13054-023-04687-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。